<SEC-DOCUMENT>0001213900-26-055466.txt : 20260513
<SEC-HEADER>0001213900-26-055466.hdr.sgml : 20260513
<ACCEPTANCE-DATETIME>20260513082424
ACCESSION NUMBER:		0001213900-26-055466
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260513
FILED AS OF DATE:		20260513
DATE AS OF CHANGE:		20260513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		26971036

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0290504-6k_ascentage.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of <B>May 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-42484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Translation of Registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 12, 2026, Ascentage
Pharma Group International issued a press releases entitled &ldquo;Ascentage Pharma to Participate in Three Upcoming Investor Conferences&rdquo;.
A copy of the press release is furnished as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit Title</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 9%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 90%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea029050401ex99-1.htm"><FONT STYLE="font-size: 10pt">Press Release dated M</FONT>ay <FONT STYLE="font-size: 10pt">1</FONT>2<FONT STYLE="font-size: 10pt">, 2026</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Date: May 13, 2026</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea029050401ex99-1.htm
<DESCRIPTION>PRESS RELEASE DATED MAY 12, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029050401_ex99-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ascentage Pharma to Present 17 Clinical Advances
at 2026 European Hematology Association Congress</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ROCKVILLE, MD and SUZHOU, China, May 12, 2026
<FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></B> Ascentage Pharma Group International (NASDAQ: AAPG; HKEX:
6855), a global, integrated biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies
for cancers and other diseases, announced today that 17 clinical advances of its core assets will be featured at the 31<SUP>st</SUP> Congress
of the European Hematology Association (EHA2026), including 8 poster presentations. The abstracts feature data from ongoing clinical studies
encompassing Olverembatinib (HQP1351), China&rsquo;s first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the
first approved&nbsp;China-developed Bcl-2 selective inhibitor. The EHA2026 Congress will convene in Stockholm, Sweden, from June 11 to
14, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As one of the most authoritative and influential
international academic meetings in hematology, the EHA Congress aggregates hematology professionals from around the world to share the
latest research advances and breakthrough clinical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Key abstracts of accepted poster presentations
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB
(HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Abstract #: PS1733</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Presentation Time: Saturday, June 13, 18:45 - 19:45 CEST</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">First Author: Weiming Li, MD, Department of Hematology, Union
Hospital, Tongji Medical College, Huazhong University of Science and Technology</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea029050401_ex99-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH
CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Abstract #: PS1727</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Presentation Time: Saturday, June 13, 18:45 - 19:45 CEST</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">First Author: Elias Jabbour, MD, Department of Leukemia,
The University of Texas MD Anderson Cancer Center</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL
REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Abstract #: PS1479</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Presentation Time: Saturday, June 13, 2026, 18:45<FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT>19:45
CEST</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">First Author: Suning Chen, The First Affiliated Hospital
of Soochow University</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CORRELATION OF BASELINE CHARACTERISTICS WITH
PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A
PIVOTAL PHASE 2 STUDY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Abstract #: PS1713</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Presentation Time: Saturday, June 13, 18:45 - 19:45 CEST</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">First Author: Keshu Zhou, Henan Cancer Hospital</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB
(HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Abstract #: PS1473</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Presentation Time: Saturday, June 13, 18:45 - 19:45 CEST</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">First Author: Jingliao Zhang, Institute of Hematology and
Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea029050401_ex99-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All abstracts (including Posters Presentation
and Publication Only) are available on the EHA website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><I>*</I></TD><TD STYLE="text-align: justify"><I>Olverembatinib and Lisaftoclax are currently under investigation
and have not yet been approved by the FDA in the US.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Ascentage Pharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ascentage Pharma Group International (NASDAQ:
AAPG; HKEX: 6855) (&ldquo;Ascentage Pharma&rdquo; or the &ldquo;Company&rdquo;) is a global, commercial stage, integrated biopharmaceutical
company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs
in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins
in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s first approved product, Olverembatinib,
is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP)
with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and
second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an
FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for
patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s second approved product, Lisaftoclax,
is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China&rsquo;s National
Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) who have previously received at least one systemic therapy including Bruton&rsquo;s tyrosine kinase (BTK) inhibitors. The Company
is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK
inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2
study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared
GLORA-4 study in patients with newly diagnosed higher risk MDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leveraging its robust R&amp;D capabilities, Ascentage
Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with
numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to
research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National
Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="ea029050401_ex99-1img1.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release includes forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.&nbsp;All statements, other than statements of historical facts, contained
in this press release may be forward-looking statements, including statements that express Ascentage Pharma&rsquo;s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.
These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma&rsquo;s filings with
the&nbsp;SEC, including those set forth in the sections titled &ldquo;Risk factors&rdquo; and &ldquo;Cautionary note regarding forward-looking
statements&rdquo; in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections
headed &ldquo;Forward-looking Statements&rdquo; and &ldquo;Risks Factors&rdquo; in the prospectus of the Company for its Hong Kong initial
public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company&rsquo;s
ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or
achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking
statements contained in this presentation do not constitute profit forecast by the Company&rsquo;s management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of these factors, you should not rely
on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are
based on Ascentage Pharma&rsquo;s current expectations and beliefs concerning future developments and their potential effects and speak
only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Contact Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Stella Yang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ascentage Pharma<BR>
Stella.Yang@ascentage.com<BR>
+1 (301) 792-6286</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Stephanie Carrington</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">ICR Healthcare<BR>
AscentageIR@icrhealthcare.com<BR>
+1 (646) 277-1282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Media Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sean Leous</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">ICR Healthcare<BR>
AscentagePR@icrhealthcare.com<BR>
+1 (646) 866-4012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea029050401_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029050401_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V *4# 2(  A$! Q$!_\0
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M_$ALOM>N22*K!&LXTD*B0$?Q _":3XY_LD>)_P!F7]M%M)U*TT3Q/XVUG7O
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MQ-'8E!(EI!=):*RI%$M8_P#P3&_X)&> OVY_@7J_QV^-?Q6\?VD4FJ:G\/\
MX?Z/X8N[)I="M?"\%O:)=:E=ZY9ZF9+&WG=8-/T&P%E:Q6D!+3#S56/>/@WP
MQDF7\39OQKQQB<#EO#'&4N$YU<@RG#9T\U^L8'#8[+L5@9PQOL*52I#$IXNG
M/$5*=%4:D(-S5F3\:N+,YS'AC)^#.!\+CLRXFX0AQ1&CGN:XG*/[*E0Q>*PN
M8X;&0EAH5JE.E+"OZM-483K*M2G;E<FO[ _"?Q4^''Q \'+X_P#!/C;PKXK\
M%/;3W@\5Z%KFG:EH"6MHAFNYIM2MKA[>W6UB4R7(G>-[= 7E5%!-?S>?#O\
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M'QR;'8G.<ZK2KYIFN8X:K0HX7,,;B%)4(8K#XC,J7U:DH82K['FO^((_8?\
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M^KTKM_N^5\J[/!]<8/;H1[_A_C2T45Y7_ _4^I_S_P PHHHH **** "BBB@
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#4?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
